Literature DB >> 34773595

Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.

V Andreasi1,2, C Ricci3,4, R Casadei3,4, M Falconi1,2, S Partelli5,6, G Guarneri1, C Ingaldi3,4, F Muffatti1, S Crippa1,2.   

Abstract

PURPOSE: Patients submitted to curative surgery for non-functioning pancreatic neuroendocrine neoplasms (NF-PanNENs) exhibit a variable risk of disease relapse. Aims of this meta-analysis were to estimate the rate of disease recurrence and to investigate the risk factors for disease relapse in patients submitted to curative surgery for NF-PanNENs.
METHODS: Medline/Pubmed and Web of Science databases were searched for relevant studies. A meta-regression analysis was performed to investigate the source of recurrence rate heterogeneity. Pooled hazard ratios (HRs) and 95% confidence intervals (95% CI) were used to assess the effect of each possible prognostic factor on disease-free survival.
RESULTS: Fifteen studies, involving 2754 patients submitted to curative surgery for NF-PanNENs, were included. The pooled rate of disease recurrence was 21% (95% CI 15-26%). Study quality (Odds ratio, OR 0.94, P = 0.016) and G3-PanNENs rate (OR 2.18, P = 0.040) independently predicted the recurrence rate variability. Nodal metastases (HR 1.63, P < 0.001), tumor grade G2-G3 (G1 versus G2: HR 1.72, P < 0.001, G1 versus G3 HR 2.57, P < 0.001), microvascular (HR 1.25, P = 0.046) and perineural (HR 1.29, P = 0.019) invasion were identified as significant prognostic factors. T stage (T1-T2 versus T3-T4, P = 0.253) and status of resection margins (R0 versus R1, P = 0.173) did not show any significant relationship with NF-PanNENs recurrence.
CONCLUSION: Disease relapse occurs in approximately one out of five patients submitted to curative surgery for NF-PanNENs. Nodal involvement, tumor grade, microvascular and perineural invasion are relevant prognostic factors, that should be taken into account for follow-up and for possible trials investigating adjuvant or neoadjuvant treatments.
© 2021. Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Curative surgery; Nonfunctioning; Pancreatic neuroendocrine neoplasms; Prognostic factors; Recurrence; Relapse

Mesh:

Year:  2021        PMID: 34773595     DOI: 10.1007/s40618-021-01705-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  45 in total

Review 1.  Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms.

Authors:  Valentina Andreasi; Francesca Muffatti; Giovanni Guarneri; Massimo Falconi; Stefano Partelli
Journal:  Curr Treat Options Oncol       Date:  2020-04-30

2.  ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.

Authors:  Stefano Partelli; Detlef K Bartsch; Jaume Capdevila; Jie Chen; Ulrich Knigge; Bruno Niederle; Els J M Nieveen van Dijkum; Ulrich-Frank Pape; Andreas Pascher; John Ramage; Nick Reed; Philippe Ruszniewski; Jean-Yves Scoazec; Christos Toumpanakis; Reza Kianmanesh; Massimo Falconi
Journal:  Neuroendocrinology       Date:  2017-02-25       Impact factor: 4.914

3.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

4.  Hereditary vasopressin-resistant urinary concentrating defects in mice.

Authors:  D V Naik; H Valtin
Journal:  Am J Physiol       Date:  1969-10

5.  Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Simron Singh; David L Chan; Lesley Moody; Ning Liu; Hadas D Fischer; Peter C Austin; Eva Segelov
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

6.  Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Simron Singh; Lesley Moody; David L Chan; David C Metz; Jonathan Strosberg; Timothy Asmis; Dale L Bailey; Emily Bergsland; Kari Brendtro; Richard Carroll; Sean Cleary; Michelle Kim; Grace Kong; Calvin Law; Ben Lawrence; Alexander McEwan; Caitlin McGregor; Michael Michael; Janice Pasieka; Nick Pavlakis; Rodney Pommier; Michael Soulen; David Wyld; Eva Segelov
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

7.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

8.  Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.

Authors:  Eric J Kuo; Ronald R Salem
Journal:  Ann Surg Oncol       Date:  2013-06-15       Impact factor: 5.344

9.  Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria.

Authors:  O M Sandvik; K Søreide; E Gudlaugsson; J T Kvaløy; J A Søreide
Journal:  Br J Surg       Date:  2015-10-29       Impact factor: 6.939

View more
  2 in total

1.  Evaluation of the Significance of Lymphatic, Microvascular and Perineural Invasion in Patients With Pancreatic Neuroendocrine Neoplasms.

Authors:  Wataru Izumo; Ryota Higuchi; Toru Furukawa; Takehisa Yazawa; Shuichiro Uemura; Yutaro Matsunaga; Masahiro Shiihara; Yukiko Takayama; Junko Tahara; Kyoko Shimizu; Katsutoshi Tokushige; Masakazu Yamamoto
Journal:  Cancer Diagn Progn       Date:  2022-03-03

Review 2.  Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.

Authors:  R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2022-08-30       Impact factor: 5.467

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.